Home/Filings/3/0001019056-17-000422
3//SEC Filing

Ardsley Partners Institutional Fund, L.P. 3

Accession 0001019056-17-000422

CIK 0001441693other

Filed

May 4, 8:00 PM ET

Accepted

May 5, 1:51 PM ET

Size

28.3 KB

Accession

0001019056-17-000422

Insider Transaction Report

Form 3
Period: 2017-04-28
Holdings
  • Common Stock

    (indirect: See Footnotes)
    3,681,580
Holdings
  • Common Stock

    (indirect: See Footnotes)
    3,681,580
Holdings
  • Common Stock

    (indirect: See Footnotes)
    3,681,580
Holdings
  • Common Stock

    (indirect: See Footnotes)
    3,681,580
Holdings
  • Common Stock

    (indirect: See Footnotes)
    3,681,580
Holdings
  • Common Stock

    (indirect: See Footnotes)
    3,681,580
Holdings
  • Common Stock

    (indirect: See Footnotes)
    3,681,580
Holdings
  • Common Stock

    (indirect: See Footnotes)
    3,681,580
Footnotes (3)
  • [F1]This Form 3 is being filed by Ardsley Advisory Partners (the " Advisor") on behalf of itself and Ardsley Partners I (the "General Partner"), Ardsley Partners Renewable Energy Fund, L.P. (the "Renewable Energy Fund"). Ardsley Partners Fund II, L.P. (the "Fund II"), Ardsley Duckdive Fund, L.P. (the "Duckdive Fund"), Ardsley Partners Institutional Fund, L.P. (the "Institutional Fund"), Ardsley Partners Advanced Healthcare Fund, L.P. (the "Healthcare Fund") and Philip J. Hempleman ("Hempleman" and, together with the Advisor, the General Partner, the Renewable Energy Fund, the Fund II, the Duckdive Fund, the Institutional Fund and the Healthcare Fund, the "Reporting Persons"). The General Partner serves as general partner to the Renewable Energy Fund, the Fund II, the Institutional Fund and the Healthcare Fund. Hempleman is the Managing Partner of the Advisor and the General Partner and serves as the general partner to the Duckdive Fund.
  • [F2]This amount reflects the amount of securities held by the Reporting Persons immediately following the transaction requiring the filing of this statement. In accordance with Instruction 5(b)(iv) of Form 3, the entire amount of the Issuer's securities held by Reporting Persons is reported herein. Each of the General Partner, the Advisor and Hempleman, disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either the General Partner and the Advisor are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  • [F3]Cont'd from Footnote 2: Hempleman is the Managing Partner of the General Partner and the Advisor and serves as the general partner to the Duckdive Fund and disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Hempleman is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Issuer

MARRONE BIO INNOVATIONS INC

CIK 0001441693

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001508581

Filing Metadata

Form type
3
Filed
May 4, 8:00 PM ET
Accepted
May 5, 1:51 PM ET
Size
28.3 KB